TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10933340
Drug: Flunitrazepam (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (highest dose)
Study: 10933340
Drug: Triazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (all doses)
Study: 674351
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 mg orally)
Study: 674351
Drug: Lofepramine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine (140 mg orally)
Study: 31279028
Drug: Crisaborole 2%
Normalized name: CRISABOROLE 2% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole 2% ointment
Study: 26082611
Drug: Amlodipine orotate/olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine orotate/olmesartan medoxomil 10/40 mg
Study: 26082611
Drug: Amlodipine besylate/olmesartan
Normalized name: Amlodipine Besylate/Olmesartan Medoxomil 5 MG-20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/olmesartan medoxomil 10/40 mg
Study: 19694343
Drug: Symbiotic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic formulation containing Lactobacillus Paracasei B 20160
Study: 17021425
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of diluted lemon juice (G4)
Study: 17021425
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of whole milk (G3)
Study: 17021425
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of water (G2)
Study: 10639609
Drug: Recombinant-methionyl human
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant-methionyl human neurotrophin-3 (r-metHuNT3) at doses ranging from 3 to 500 microg/kg/day
Study: 7506158
Drug: Oral nimesulide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nimesulide 300 mg/day
Study: 7506158
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 150 mg/day
Study: 7506158
Drug: Rectal nimesulide
Normalized name: nimesulide Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal nimesulide 400 mg/day
Study: 7506158
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 200 mg/day
Study: 30203153
Drug: MTX/UST combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX/UST combination therapy
Study: 30203153
Drug: UST monotherapy
Normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UST monotherapy
Study: 27507876
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 on day 1 of every 21-day cycle) plus gefitinib (250 mg/d)
Study: 24730621
Drug: Surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical periodontal therapy with initial scaling and root planing
Study: 24730621
Drug: Surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical periodontal therapy without initial scaling and root planing
Study: 22646067
Drug: Glycopyrrolate oral
Normalized name: glycopyrrolate Oral Tablet
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate oral solution
Study: 11104295
Drug: pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill placebo
Study: 17509314
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily until stone clearance or for a maximum of 30 days)
Study: 17509314
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily until stone clearance or for a maximum of 30 days)
Study: 12352802
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose and fractional three dose schedules of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Study: 12352802
Drug: Three half-doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three half-doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Study: 12352802
Drug: All dosing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing regimens of polyribosylribosyl phosphate-tetanus toxoid conjugate vaccine
Study: 9915318
Drug: Epidural alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural alfentanil (400 microg bolus + a 400‐microg/h infusion for 2 h)
Study: 9915318
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil (computer-controlled infusion)
Study: 7844365
Drug: Didanosine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine monotherapy or combination therapy with zidovudine
Study: 28241133
Drug: Sertraline (intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (intervention in a multicentre randomised placebo-controlled trial)
Study: 19332455
Drug: Early eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early eptifibatide (two boluses of 180 microg/kg administered 10 minutes apart, and a standard infusion for >= 12 hours before angiography)
Study: 19332455
Drug: Delayed eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed eptifibatide (matching placebo infusion with provisional use after angiography)
Study: 17357577
Drug: Alpha dihydroergocryptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha dihydroergocryptine (10 mg tablets)
Study: 11547705
Drug: Monthly educational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly educational session (control)
Study: 29347946
Drug: Vibrotactile sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vibrotactile sensory augmentation during balance training
Study: 29347946
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sensory augmentation)
Study: 25039978
Drug: Esomeprazole or
Normalized name: esomeprazole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole or AZD0865 (potent acid suppression treatment)
Study: 2044903
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (40 mg)
Study: 8513981
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (80 mg)
Study: 22533516
Drug: Spiritual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiritual therapy intervention
Study: 7554633
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose unfractionated heparin
Study: 19731307
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose rituximab (375 mg/m2 x 4)
Study: 19731307
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose rituximab (DDR)
Study: 16706755
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa extract (CRS) applied twice daily for 3 months
Study: 16706755
Drug: Tissue Nutrient
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Nutrient Solution Recovery Complex (TNS) applied twice daily for 3 months
Study: 16706755
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (Vit C) cream applied twice daily for 3 months
Study: 11397885
Drug: 10% lipid
Normalized name: Liposyn II 10% Lipid Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lipid emulsion infusion + heparin (n = 15)
Study: 11397885
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (control study; n = 15)
Study: 11397885
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin treatment after 3 months (n = 30)
Study: 7944453
Drug: Intraaortic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic chemotherapy (IA)
Study: 31642037
Drug: Brexanolone injection
Normalized name: brexanolone Injection
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brexanolone injection
Study: 24490025
Drug: Sertindole (16-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (16-24 mg)
Study: 19542525
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg)
Study: 20728522
Drug: gp120/NefTat candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS01(B)
Study: 20728522
Drug: gp120/NefTat candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS02(A)
Study: 20728522
Drug: gp120/NefTat candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS02(V)
Study: 20728522
Drug: gp120/NefTat candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120/NefTat candidate HIV-1 vaccine
Study: 18991469
Drug: LNX‐QR 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNX‐QR 8 mg tablet
Study: 18991469
Drug: LNX‐ST 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNX‐ST 8 mg tablet
Study: 11798692
Drug: Losec (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losec (40 mg)
Study: 11798692
Drug: Aoke‐Changzhou No.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aoke‐Changzhou No.4 Pharm (40 mg)
Study: 11798692
Drug: Omeprazole‐Sanye Pharm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole‐Sanye Pharm (40 mg)
Study: 8683228
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and fluorouracil (M‐‐>F)
Study: 6348763
Drug: Steroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids or chlorambucil given in alternate months for a cumulative period of six months
Study: 6348763
Drug: Steroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids or chlorambucil
Study: 28554173
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day
Study: 25367235
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg administered 2 minutes before aortic declamping)
Study: 25367235
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg intravenously administered 15 minutes before release of aortic cross clamp)
Study: 22965962
Drug: (ziv‐)aflibercept 6
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (ziv‐)aflibercept 6 mg/kg IV + docetaxel 75 mg/m²
Study: 22965962
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + docetaxel 75 mg/m²
Study: 15924594
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg on-demand
Study: 12590989
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of in-person with physician letter
Study: 10496434
Drug: d,l-sotalol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-sotalol 80 mg twice daily
Study: 10496434
Drug: d,l-sotalol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-sotalol 120 mg twice daily
Study: 10496434
Drug: d,l-sotalol 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-sotalol 160 mg twice daily
Study: 1745318
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 9 g/24 hours
Study: 1745318
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 6 g/24 hours
Study: 31277184
Drug: 25G needle
Normalized name: NEEDLE 25G 1IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25G needle through the lateral crypt (group L, n=30)
Study: 22119244
Drug: K-134 50
Normalized name: K-134
DrugBank: K-134 (DB12685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-134 50 mg
Study: 22119244
Drug: K-134 100
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-134 100 mg
Study: 17503880
Drug: Next generation
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next generation drug-eluting stents (including sirolimus analogs, biodegradable and bioabsorbable materials)
Study: 17503880
Drug: Reservoir stents
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir stents with different drug release profiles
Study: 15489844
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus tianeptine 37.5 mg/day
Study: 16123227
Drug: Clonidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (15 mg/week for 8 weeks)
Study: 27937084
Drug: Rebamipide (REB)
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide (REB) ophthalmic suspension
Study: 27937084
Drug: Diquafosol (DQS)
DrugBank: Diquafosol (DB15919)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Diquafosol (DQS) ophthalmic solution
Study: 26785125
Drug: Self-reported frequency
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported frequency of doses taken
Study: 26785125
Drug: Self-reported percentage
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported percentage of doses taken
Study: 26785125
Drug: Unannounced pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unannounced pill counts (UPC)
Study: 26785125
Drug: Plasma tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plasma tenofovir levels (SSDD; ≥40 ng/ml)
Study: 24504688
Drug: Metoclopramide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (7 mg) plus dimeticone (40 mg) and pepsin (50 mg)
Study: 24504688
Drug: Conventional metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoclopramide capsule (7 mg)
Study: 21750253
Drug: QUI (quinapril)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUI (quinapril) 40 mg/d
Study: 21750253
Drug: QUI +
Normalized name: Quinidine
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QUI + ALA (quinapril 40 mg/d + α-lipoic acid 600 mg/d)
Study: 17445589
Drug: Alendronate 35
Normalized name: ALENDRONATE 35MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 35 mg/wk for 6 months (Group A)
Study: 9803777
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet with hypercaloric supplement (Suplena)
Study: 9803777
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same low-protein diet, 0.6 g protein/kg/day)
Study: 28182279
Drug: AMIO +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMIO + RAN (1 g oral dose)
Study: 28182279
Drug: AMIO (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMIO (5 mg/kg loading dose followed by 50 mg/h)
Study: 21714757
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg) administered daily for four weeks
Study: 21714757
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for four weeks
Study: 19781325
Drug: Hyperoxygenated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxygenated solution (HO group, n = 109)
Study: 19781325
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (NO group, n = 115)
Study: 3541602
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 mg two times daily to maximum of 20 mg per day)
Study: 3541602
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg three times daily to a maximum of 450 mg per day)
Study: 31593299
Drug: 5 mL lidocaine
Normalized name: lidocaine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL lidocaine 2% diluted in 15 mL normal saline
Study: 31593299
Drug: 20 mL normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL normal saline alone
Study: 19293592
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade with ACE inhibitor and angiotensin II receptor blocker
Study: 16437672
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g twice a day)
Study: 10496437
Drug: candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: candesartan cilexetil 8 mg once daily
Study: 10496437
Drug: candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: candesartan cilexetil 16 mg once daily
Study: 30588956
Drug: Advagraf (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advagraf (once-daily tacrolimus)
Study: 30588956
Drug: Prograf (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf (twice-daily tacrolimus)
Study: 26767411
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (SC) 50 mg capsules, maximum 150 mg, given eight hourly during labour
Study: 26767411
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given eight hourly during labour
Study: 24694207
Drug: Self-Management education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Management education for epilepsy (SMILE (UK) course with treatment as usual)
Study: 22316315
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel containing isoflavones, Lactobacillus sporogenes, Calendula officinalis extract and lactic acid (Estromineral Gel, Rottapharm‐Madaus) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Study: 22316315
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical treatment (NT) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Study: 20807792
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm l‐NAME
Study: 20807792
Drug: Combined 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 20 mm capsazepine + 10 mm l‐NAME
Study: 20807792
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (90% propylene glycol + 10% lactated Ringer solution)
Study: 16097707
Drug: antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibacterial therapy
Study: 16097707
Drug: antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibacterial therapy + alpha-adrenoblockers
Study: 16097707
Drug: antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibacterial therapy + transrectal laser and magnetic physiotherapy
Study: 16097707
Drug: antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibacterial therapy + alpha-adrenoblockers + transrectal laser and magnetic physiotherapy
Study: 11849155
Drug: Allogeneic human
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic human tumour cell vaccine with Mycobacterium vaccae (SRL‐172)
Study: 7581527
Drug: BCG full
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG full dose
Study: 2184287
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (5 mg/kg over 20 minutes)
Study: 2184287
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine (400 mg immediately and 400 mg in 4 hours)
Study: 6115246
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) (200 mg/day)
Study: 6115246
Drug: Mebendazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (2 g/day)
Study: 6115246
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg per week)
Study: 27191247
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of red grape seed extract (RGSE) for eight weeks
Study: 18030411
Drug: Postoperative multidisciplinary,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative multidisciplinary, multifactorial fall-prevention program including staff education, systematic assessment and treatment of fall risk factors, vitamin D and calcium supplementation
Study: 16816303
Drug: Risperidone or
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone or Haloperidol (flexible dose, median treatment length 206 days)
Study: 12816293
Drug: Herbal-based mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal-based mouthrinse with oral irrigator
Study: 12816293
Drug: Conventional mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mouthwash with oral irrigator
Study: 30048547
Drug: Oligofructose (OF)
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (OF) 7g twice daily
Study: 30048547
Drug: Maltodextrin (MD)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (MD) 7g twice daily
Study: 27235528
Drug: Mobi-C implant
Normalized name: Synovex C Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobi-C implant